JWH-018 Stats - Substance Search

Pharmacology

DrugBank

Mechanism of Action

... JWH-018 is probably the most studied synthetic cannabinoid. It has been found in multiple preparations and has been shown to be a potent cannabinoid receptor (CB) agonist. CB1 is the principal receptor thought to be most highly responsible for the euphoria and psychoactive effects of THC. The CB2 receptor resides mostly in the immune system but has some effect on pain control and mood regulation. ...

Metabolism

... The high pharmacological and addictive potency of JWH-018 highlights the importance of elucidating the metabolism of JWH-018, without which a meaningful insight into its pharmacokinetics and its toxicity would not be possible. In the present study, the cytochrome P450 phase I metabolites of JWH-018 were investigated, after in vitro incubation of the drug with human liver microsomes, followed by liquid chromatography-tandem mass spectrometry analysis. This revealed monohydroxylation of the na

Receptor Profile

Receptor Actions

Agonists

CB1 receptor agonist (full)

CB2 receptor agonist (full)

Measured Affinities

Guide to PHARMACOLOGY

Measured binding and functional data for JWH-018, curated by the IUPHAR/BPS Guide to PHARMACOLOGY. Each row cites the paper it came from. Lower concentrations mean tighter binding — a value in the sub-nanomolar range indicates a very potent interaction.

Target	Action	Measure	Value	Concentration	Species	Source
CB2 receptor CNR2	Full agonist	pKi	8.5	3.16 nM	Human	PMID 10525107
CB1 receptor CNR1	Full agonist	pKi	8	10 nM	Human	PMID 10525107

Reading this. pKi, pEC50 and pIC50 are negative log molar values, so a higher number means a tighter interaction; the concentration column converts them for you. Values from non-human species are laboratory measurements and do not translate directly to human effect. Receptor affinity is not a dose — it describes what a molecule binds, not how much of it is safe to take.

Receptor data from the IUPHAR/BPS Guide to PHARMACOLOGY (v2026.2), licensed CC BY-SA 4.0. Matched to this substance by InChIKey.

History & Culture

JWH-018 was synthesized by John W. Huffman, an organic chemist at Clemson University, as part of his research into compounds affecting the endocannabinoid system. The compound's designation derives from Huffman's initials.

2006–present

Beginning in 2006, products containing JWH-018 entered the grey market under the brand name Spice, sold as potpourri or incense and labeled "not for human consumption" to circumvent drug regulations. The brand expanded into a product family including Spice Gold, Spice Arctic Synergy, Spice Diamond, and Spice Tropical Synergy. On 15 December 2008, German pharmaceutical analysis identified JWH-018 as one of the active components in at least three versions of Spice products. The Spice brand became so influential that the term eventually came to be used generically to describe all synthetic cannabinoids, regardless of their specific chemical composition. Following regulatory bans, manufacturers demonstrated a pattern of circumventing controls through minor chemical modifications—analysis of products obtained four weeks after German prohibition found manufacturers had shortened the alkyl chain by one carbon atom to create technically distinct compounds.

Subjective Effects

Physical

Spontaneous tactile sensations: The body high of JWH-018 can be described as a warm, soft, pleasurable, all-encompassing tingling sensation that spreads over the body. It maintains a consistent presence that quickly rises with the onset and hits its limit once the peak has been reached before immediately dissipating.
Sedation: Generally, the effects on the user's energy levels are sedating. This encourages one to relax, lie down, and (at higher doses) fall asleep. It produces strong sedative effects that can be described as on par with 5F-PB-22 and more sedating when compared to THC, JWH-073, THJ-018, AM-2201, or 5F-UR-144 but less than that of 5F-AKB-48.
Motor control loss: This substance causes a partial to moderate suppression of motor control which intensifies proportional to dose, but rarely results in a complete inability to walk and perform basic movements.
Appetite enhancement: As with many other cannabinoids, JWH-018 causes an increase in appetite, known colloquially as "the munchies" in popular American and United Kingdom culture. Clinical studies and survey data have found that cannabis increases food enjoyment and interest in food. This is thought to be due to the way in which endocannabinoids in the hypothalamus activate cannabinoid receptors that are responsible for maintaining food intake.
Dehydration: This is known colloquially as "cotton mouth" in popular American and United Kingdom culture.
Vasodilation: Cannabinoids appear to decrease blood pressure by dilating the blood vessels and increasing blood flow throughout the body. The arteries in the eyeball expand from the decreased blood pressure and the heart rate increases to compensate for the reduction in pressure.
Pain relief: Cannabinoids have been clinically demonstrated to provide pain relief via agonism of cannabinoid receptors CB1 and CB2, which extends to synthetic cannabinoid receptor agonists.
Perception of increased weight or Perception of decreased weight
Changes in gravity: JWH-018, like other cannabinoids, is capable of causing vertigo with which the environment appears to be spinning or oscillating. At moderate doses, it can spontaneously induce the sensation of falling, which can be overwhelming and uncomfortable. The propensity of this is greatly reduced and eliminated in proportion to tolerance.

Cognitive

Current mind state enhancement: The most prominent cognitive component of cannabinoids is the way in which they enhance the emotions one is already feeling proportional to dose. This can result in euphoria, extreme laughter, and increased immersion within tasks and activities, or it can result in anxiety and paranoia depending on the user's current mind state.
Euphoria: This can be considered very prominent in comparison to THJ-018, AM-2201, and 5F-UR-144 but less intense in comparison to JWH-073.
Thought connectivity: This can attribute to fluid, more abstract thinking in comparison to linear thought.
Anxiety: Subjectively, JWH-018 is less anxiogenic and stimulating than Δ9-THC, THJ-018, AM-2201, or 5F-UR-144 but more so than JWH-073.
Paranoia: All cannabinoids are capable of inducing paranoia at high doses or with chronic administration.
Thought deceleration
Immersion enhancement
Conceptual thinking
Mindfulness
Information processing suppression
Dream suppression

Sensory

Auditory

Enhancements

Visual

Colour enhancement
Acuity suppression
Geometry: As reported with other cannabinoids, JWH-018 can produce closed eye visuals at moderate doses, which can escalate into visual distortions such as a ripples in the field of vision upon continuous administration. Within users who also regularly use psychedelics, it is capable of inducing these consistently in a visual style which seems to be an averaged out depiction of all the psychedelics one has used within the past. These rarely extend beyond level 4 and are considered to be mild, fine, small and zoomed out but brighter and better defined than the geometry experienced with cannabis.

Forked from Subjective Effect Documentation work by Josie Kins, September 2015. Via dose.wiki (CC0).

Toxicity

PsychonautWiki

The toxicity and long-term health effects of recreational JWH-018 use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown. This is because the drug has very little history of human usage. JWH-018, like many synthetic cannabinoids, is a full agonist of the CB1 receptors in contrast to the partial agonist Δ9-THC. Because of this, harm mediated by CB1 receptor agonism can be more severe than its partial agonist counterparts. JWH-018 has caused seizures and convulsions, and evidence suggests this is a result of inhibiting GABA neurotransmission more effectively than Δ9-THC.

Tolerance & Pharmacokinetics

drugs.wiki

Half-Life

1.3 – 5.7 h (biphasic; median ~1.7 h after inhalation; estimates vary by study)

Addiction Potential

Moderate-to-high. Full CB1 agonism with rapid tolerance and withdrawal reported (anxiety, irritability, tremor, sweating) after sustained daily use; emergency data show dependence/withdrawal and severe presentations more often than with cannabis.

Tolerance Decay

Full tolerance 1d Half tolerance 7d Baseline ~14d

Anecdotal and limited preclinical data suggest rapid tachyphylaxis with daily use; spacing days between sessions reduces tolerance and likely risk. Data quality is mixed and skewed to user reports.

Cross-Tolerances

Δ9-THC (cannabis)

Other indole SCs (e.g., JWH-073, AM-2201)

Experience Report Analysis

Erowid BlueLight

106 Reports

80 Single-substance

2008–2014 Date Range

92 With Age Data

31 Effects Detected

Demographics

Gender Distribution

Age Distribution

Reports Over Time

Effect Analysis

Erowid + Bluelight

Effects aggregated from 114 experience reports (80 single-substance Erowid + 34 Bluelight)

114 Reports

112 Effects Detected

27 Positive

65 Adverse

20 Neutral

Effect Sentiment Distribution

Confidence Distribution

Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.

Positive Effects 27

Euphoria 29.8% 87%

Stimulation 22.8% 81%

Music Enhancement 20.2% 87%

Body High 20.2% 88%

Color Enhancement 15.0% 78%

Hypersomnia 14.7% 79%

Empathy 12.2% 85%

Joy 11.8% 82%

Introspection 9.6% 78%

Sociability Enhancement 8.8% 83%

Tactile Enhancement 8.7% 70%

Focus Enhancement 6.1% 85%

Insight 5.9% 75%

Brightness Enhancement 5.9% 82%

Creativity Enhancement 4.4% 75%

Pain Relief 4.4% 80%

Lightness 2.9% 75%

Awe 2.9% 70%

Contact-With-Presence 2.9% 75%

Giggles 2.9% 75%

Adverse Effects 65

Anxiety 56.1% 88%

Body Load 35.3% 83%

Fear 29.4% 92%

Confusion 28.0% 87%

Nausea 25.4% 85%

Motor Impairment 23.6% 88%

Thought Disorganization 23.5% 80%

Panic 23.5% 91%

Thought Acceleration 20.6% 78%

Dry Mouth 20.6% 84%

Paranoia 17.6% 86%

Dizziness 17.6% 88%

Body Temperature Change 17.6% 85%

Memory Suppression 17.5% 83%

Increased Heart Rate 15.0% 70%

Time Dilation 14.7% 83%

Pain Enhancement 14.7% 79%

Tremor 14.7% 89%

Heaviness 14.7% 83%

Depersonalization 11.8% 81%

⚠ Seizure 7.5% 70%

⚠ Psychosis 3.8% 70%

⚠ Chest Pain 2.9% 90%

Show 42 more adverse effects

Focus Suppression 11.8% 80%

Headache 11.4% 83%

Muscle Spasm 8.8% 88%

Pressure 8.8% 78%

Delusion 8.8% 80%

Pupil Dilation 7.0% 87%

Muscle Tension 6.1% 85%

Pulse Racing 5.9% 88%

Visual Fragmentation 5.9% 80%

Ataxia 5.9% 82%

Dysphoria 5.9% 88%

Involuntary Movements 5.9% 88%

Entity Imagery 5.9% 75%

Disinhibition 2.9% 75%

Tinnitus 2.9% 75%

Burning Sensation 2.9% 85%

Skin Crawling 2.9% 80%

Cognitive Change 2.9% 75%

Insomnia 2.9% 85%

Visual Suppression 2.9% 75%

Auditory Suppression 2.9% 75%

Amnesia 2.9% 90%

Genital Sensitivity Change 2.9% 75%

Frequent Urination 2.9% 75%

Thought Loops 2.9% 90%

Derealization 2.9% 90%

Environmental Transfiguration 2.9% 85%

Tactile Suppression 2.9% 80%

Vomiting 2.9% 90%

Nightmares 2.9% 80%

Shadow Imagery 2.9% 85%

Restless Legs 2.9% 85%

Near-Death Experience 2.9% 90%

Memory Enhancement 2.9% 80%

Melting/flowing 2.9% 80%

Crying 2.9% 90%

Visual Vibration 2.9% 90%

Jaw Clenching 2.9% 90%

Blurred Vision 2.9% 85%

Chills 2.9% 85%

Temporal Disorientation 2.9% 85%

Catatonia 2.9% 85%

Show 20 neutral or unclassified mentions

Visual Distortions 27.2%

Hospital 25.0%

Numbness 23.5%

Sedation 21.9%

Auditory Effects 20.1%

Dissociation 14.1%

Time Distortion 13.8%

Appetite Increase 11.8%

Ego Dissolution 10.0%

Closed-Eye Visuals 8.8%

Tingling 8.8%

Open-Eye Visuals 7.5%

Time Compression 5.9%

Muscle Twitching 5.9%

Restlessness 5.9%

Depth Distortion 2.9%

Motor Automatisms 2.9%

Flushing 2.9%

Isolation Preference 2.9%

Thought Deceleration 2.9%

Also reported in combinations. In the 26 JWH-018 reports where another drug was taken too, 6 (23.1%) mention hospital, emergency services or an overdose, 3 (11.5%) a seizure and 0 (0.0%) psychosis. In the 80 single-substance reports: 25.0%, 7.5% and 3.8%. These are not in the figures above: they cannot be put down to JWH-018 alone, and a mention is not always something that happened to the writer.

Dosage Distribution

Dose distribution from experience reports, one dose per report (the first listed). Doses above Q3 + 3×IQR, far above what people typically take, are left out of the median and range and listed under each route: most are real heavy doses or overdoses, not mistakes.

Median: 5.5 mg IQR: 3.8–18.8 mg n=20

1 dose more than 50 times the median may be a typing or unit error and is not in the figures either: check the report.

Show the report

Possibly a typing or unit error:

10,000 mg

Real-World Dose Distribution

Erowid

From 38 of 56 recorded dose entries: those that state a weight (mg, g or µg), in routes with at least five of them. Values above Q3 + 3×IQR, far above what people typically take, are left out; they can include real heavy doses and overdoses, not only mistakes.

Smoked (n=29)

Median: 6.0mg 25th: 2.0mg 75th: 10.0mg 90th: 22.0mg

Oral (n=7)

Median: 7.0mg 25th: 4.0mg 75th: 16.0mg 90th: 31.0mg

Common Combinations

Most co-occurring substances, as a share of all 106 reports filed under JWH-018; whiskers are 95% intervals

Form / Preparation

Most common forms and preparations, as a share of the 74 reports that give one; whiskers are 95% intervals

Body-Weight Dosing

Dose per kg of body weight, one dose per report (the first listed), from reports giving a weight of 30–250 kg. Doses above Q3 + 3×IQR, far above what people typically take, are left out of the median and range and listed under each route.

Smoked

Median: 0.068 mg/kg IQR: 0.036–0.278 mg/kg n=20

1 dose more than 50 times the median may be a typing or unit error and is not in the figures either: check the report.

Show the report

Possibly a typing or unit error:

137.741 mg/kg

Oral

Median: 0.091 mg/kg IQR: 0.051–0.241 mg/kg n=7

Redose Patterns

Redosing behavior across 80 reports

12.5% Redosed

1.1 Avg Doses

110m Median Interval

Legal Status

Country	Status	Notes
United Kingdom	Controlled (Misuse of Drugs Act)	Classified under the Misuse of Drugs Act at the end of 2009. JWH-018 was among the first synthetic cannabinoids to be formally controlled in the UK, prompted by its widespread availability in products marketed as 'Spice' or herbal incense.
United States	Schedule I	Placed under federal control during the summer of 2012. Prior to scheduling, JWH-018 was sold openly in head shops and online under the guise of incense or potpourri labeled 'not for human consumption' to circumvent drug laws.

Harm Reduction

drugs.wiki

JWH‑018 is a full CB1 agonist with near-maximal efficacy (unlike Δ9‑THC’s partial agonism), yielding a much steeper dose‑response and a narrow safety margin—small increments can cause outsized effects. Blends sold as ‘Spice/K2’ are highly variable and often contain multiple or different noids than advertised; potency ‘hot‑spots’ and adulteration are common, so homogenization or volumetric preparation is safer than sprinkling on plant material. Inhalation peaks within minutes, making rapid redose tempting; wait ≥15 minutes between tiny measured inhalations to gauge effect and avoid panic reactions, vomiting, or syncope. Prominent toxicity signs include severe anxiety/agitation, tachycardia/hypertension, emesis, seizures, psychosis, and hyperthermia; seek urgent care for chest pain, persistent confusion, or any seizure. First-line ED care is supportive with benzodiazepines for agitation/seizures and active cooling/hydration; there is no specific antidote. Seizure risk appears higher with synthetic cannabinoids than with cannabis; combining with bupropion, tramadol, or stimulants adds further risk. Oral use has slower onset and a longer, less predictable course—common overdose pattern is early redose before the first dose peaks. Heavy cannabis tolerance does not protect against JWH‑018; tolerance builds rapidly, but cross‑tolerance is incomplete and does not prevent adverse reactions. Avoid driving and hazardous tasks for several hours after use; effects on coordination and judgment can persist beyond the perceived ‘high’. Pregnancy and lactation: cannabinoids cross the placenta and concentrate in breast milk; synthetic analog effects are poorly defined—avoid exposure. Routine reagent kits are not reliable for identifying specific noids; only accredited lab analysis can confirm identity/potency.

JWH-018 Stats & Data

Pharmacology

Mechanism of Action

Metabolism

Receptor Profile

Receptor Actions

Measured Affinities

History & Culture

2006–present

Subjective Effects

Physical

Cognitive

Sensory

Toxicity

Tolerance & Pharmacokinetics

Tolerance Decay

Cross-Tolerances

Experience Report Analysis

Demographics

Gender Distribution

Age Distribution

Reports Over Time

Effect Analysis

Effect Sentiment Distribution

Confidence Distribution

Positive Effects 27

Adverse Effects 65

Dosage Distribution

Real-World Dose Distribution

Smoked (n=29)

Oral (n=7)

Common Combinations

Form / Preparation

Body-Weight Dosing

Smoked

Oral

Redose Patterns

Legal Status

Harm Reduction

References

Data Sources

Cited References

Additional references